This study is to describe the treatment rates for adjuvant anti-PD1 antibody therapy in patients with resected stage IIB/IIC cutaneous melanoma and to describe determinants for recommendations of treating physicians and/or interdisciplinary tumor boards about adjuvant treatment in Stage IIB/IIC resected melanoma. The study is also to describe motivations of declining recommended/offered adjuvant treatment among patients with resected Stage IIB/IIC melanoma.
